Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Benzer Materyaller

• Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy
  Yazar:: Gerrard, Mary, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group
  Yazar:: Cairo, Mitchell, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study
  Yazar:: Cairo, Mitchell S., ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
  Yazar:: Cairo, Mitchell S., ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell Non-Hodgkin’s Lymphoma: Results of the FAB/LMB 96 international study
  Yazar:: Poirel, HA, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)